Lv46
538 积分 2023-02-16 加入
Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial
12小时前
已关闭
Real-world data of cadonilimab in recurrent or metastatic cervical cancer in China: a multicentric study
1天前
已完结
Safety and efficacy of neoadjuvant toripalimab plus chemotherapy followed by chemoradiotherapy for locally advanced esophageal squamous cell carcinoma in China (GASTO 1071): a non-randomised, two-cohort, phase 2 trial
1天前
已完结
New exploration of KRASG12D inhibitors and the mechanisms of resistance
1天前
已完结
Nivolumab and Ipilimumab for Metastatic Castration-Resistant Prostate Cancer With an Immunogenic Signature: The Multicenter, Two-Cohort, Phase II NEPTUNES Study
1天前
求助中
Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer
1天前
已完结
Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated results from cohort 5 in the DUBHE-L-201 study
2天前
已完结
Nivolumab and Ipilimumab for Metastatic Castration-Resistant Prostate Cancer With an Immunogenic Signature: The Multicenter, Two-Cohort, Phase II NEPTUNES Study
4天前
求助中
Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer
7天前
已完结
Cadonilimab (a PD-1/CTLA-4 bispecific antibody) Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase Ⅱ Clinical Trial
7天前
已完结
皖公网安备34019202002308
